[Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response?]

Autor:	Mariadelina Simeoni, Paola Cianfrone, Nicola Comi, Innocenza Gentile, Flora Fortunata Fabiano, Valentina Piraina, Roberta Talarico, Gaetano Lucisano, Laura Rivoli, Michele Andreucci, Laura Fuiano, Daniela Foti, Elio Gulletta, Giorgio Fuiano
Přispěvatelé:	Simeoni, Mariadelina, Cianfrone, Paola, Comi, Nicola, Gentile, Innocenza, Fortunata Fabiano, Flora, Piraina, Valentina, Talarico, Roberta, Lucisano, Gaetano, Rivoli, Laura, Andreucci, Michele, Fuiano, Laura, Foti, Daniela, Gulletta, Elio, Fuiano, Giorgio
Rok vydání:	2015
Předmět:	Adult Male Analysis of Variance Cross-Over Studies Time Factors Angiotensin-Converting Enzyme Inhibitors Pilot Projects Middle Aged Drug Administration Schedule Proteinuria Ramipril Hypertension Humans Female Kidney Diseases Prospective Studies Antihypertensive Agents Aged
Zdroj:	Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia. 32(1)
ISSN:	1724-5990
Popis:	BACKGROUND: Ramipril administered once daily is characterized by an attenuation of its pharmacological activity in the following 24 hours, whose effects on antiproteinuric activity have not yet been investigated.METHODS: The antiproteinuric efficacy of Ramipril has been evaluated in a cross-over study in 20 patients with renal disease, proteinuria and hypertension (GFR50 mL / min, proteinuria
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::72d8af2f0219db2a9715212f7128f7e3 https://pubmed.ncbi.nlm.nih.gov/25774586 Zobrazit plný text záznamu